Cytokinetics to Participate in Upcoming Investor Conferences
June 14 2016 - 3:00PM
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I.
Blum, President and Chief Executive Officer, is scheduled to
present at the JMP Securities 2016 Life Sciences Conference on June
21, 2016 at 1:00 PM EDT at the St. Regis Hotel, New York, NY.
Members of Cytokinetics' senior management team will also
participate in the 3rd Annual ROTH Healthcare Day on June 22, 2016
at The Dorchester Hotel in London, UK.
Interested parties may access the live webcast
of the JMP Securities presentation by visiting the Investors &
Media section of the Cytokinetics website at www.cytokinetics.com.
The webcast replay of the presentation will be archived on the
Presentations page within the Investors & Media section of
Cytokinetics' website 90 days following the conclusion of the
event.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical company focused
on discovering, developing and commercializing first-in-class
muscle activators as potential treatments for debilitating diseases
in which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to increase muscle function and
contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a
fast skeletal muscle troponin activator, for the potential
treatment of ALS. Tirasemtiv has been granted orphan drug
designation and fast track status by the U.S. Food and Drug
Administration and orphan medicinal product designation by the
European Medicines Agency for the potential treatment of ALS.
Cytokinetics retains the right to develop and commercialize
tirasemtiv. Cytokinetics is collaborating with Amgen Inc. to
develop omecamtiv mecarbil, a novel cardiac muscle activator, for
the potential treatment of heart failure. Cytokinetics is
collaborating with Astellas Pharma Inc. to develop CK-2127107, a
fast skeletal muscle activator, for the potential treatment of
spinal muscular atrophy and chronic obstructive pulmonary disease.
Amgen holds an exclusive license worldwide to develop and
commercialize omecamtiv mecarbil and Astellas holds an exclusive
license worldwide to develop and commercialize CK-2127107. Both
licenses are subject to Cytokinetics' specified development and
commercialization participation rights. For additional information
about Cytokinetics, visit http://www.cytokinetics.com/
Contact:
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(650) 624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2024 to May 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From May 2023 to May 2024